Literature DB >> 1693591

Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies.

J Y Ro1, D J Grignon, A G Ayala, P L Fernandez, N G Ordonez, K I Wishnow.   

Abstract

Twelve patients with primary mucinous adenocarcinoma of the prostate were included in a clinicopathologic study; criteria included a total tumor volume more than 25% mucinous and single or clustered tumor cells floating in mucin lakes. Patient ages were 57 to 81 years; tumor stages were C (three), D (five), and unknown (four). Bone was the most frequent metastatic site (usually osteoblastic), followed by lymph nodes and lungs. Serum levels of prostatic acid phosphatase and prostate-specific antigen were frequently elevated (five of 10 and three of three measured, respectively). All mucinous adenocarcinomas also contained other histologic patterns: microglandular (four), cribriform (three), comedo (two), solid (two), and hypernephroid (one). Mucinous components composed less than 50% of three tumors, 50% and 75% of six, and more than 75% of three. No tumor contained signet-ring cells. Immunoperoxidase staining was positive for prostatic acid phosphatase and prostate-specific antigen and negative for carcinoembryonic antigen. Treatment was radiation, estrogen, orchiectomy, or a combination. In two of four patients, serum prostatic acid phosphatase levels normalized after therapy. Seven patients died of disease (mean follow-up, 56 months), and five patients are alive with disease (mean, 32.2 months). The proportion of mucinous component did not affect prognosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693591     DOI: 10.1016/s0046-8177(96)90004-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  Incidental discovery of mucinous adenocarcinoma of the prostate following transurethral resection of the prostate: A report of two cases and a literature review.

Authors:  Lijie Zhang; Lihua Zhang; Ming Chen; Quan Fang
Journal:  Mol Clin Oncol       Date:  2018-07-30

2.  Collagenous micronodules in prostate cancer revisited: are they solely associated with Gleason pattern 3 adenocarcinomas?

Authors:  Mi J Kim; Mukul K Divatia; Jeong H Lee; Steven Shen; Brian J Miles; Jun H Hwang; Alberto G Ayala; Jae Y Ro
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 3.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

4.  Management about intravesical histological transformation of prostatic mucinous carcinoma after radical prostatectomy: A case report.

Authors:  Sheng-Jiang Bai; Li Ma; Min Luo; Hang Xu; Lu Yang
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

5.  Prostate carcinomas mimicking a digestive malignancy.

Authors:  Sorin Dema; Alis Liliana Carmen Dema; Sorina Tăban; Bianca Roxana Natarâş; Livius Cosmin Daminescu; Ciprian Constantin Duţă; Alin Adrian Cumpănaş; Tiberiu Răzvan Bardan
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

6.  Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation.

Authors:  Christos Kalaitzis; Michael Koukourakis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; Efthimios Sivridis; Athanasios Bantis; Stavros Touloupidis
Journal:  Case Rep Urol       Date:  2014-01-29

7.  Co-existence of mucin-producing urothelial-type adenocarcinoma of the prostate and inverted papilloma of the bladder.

Authors:  Xiao-Nan Mu; Si-Jun Wang; Zhi-Gang Sun; Min Zhang; Zhe Li; Long-Yang Zhang
Journal:  Contemp Oncol (Pozn)       Date:  2017-06-30

8.  Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation.

Authors:  Yao Zhang; Hua Shen; Kai Liao; Weili Wu; Jiuming Li; Hongbo Yu; Hongfei Wu; Zengjun Wang
Journal:  Front Oncol       Date:  2020-12-23       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.